Complete withdrawal of glucocorticoids after dupilumab therapy in allergic bronchopulmonary aspergillosis: A case report

doi:10.12998/wjcc.v9.i23.6922

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 9, Issue 23

This Article

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (8788)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-1) series.

Item

Count

PDF

474

WORD

115

HTML

4069

Figures (1-2)

714

Tables (1-1)

653

Sum=6025

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1094

Download

1680

Sum=2774

Aug 16, 2021 (publication date) through Feb 28, 2026

Times Cited of This Article

Times Cited (16)

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

- Full Article with Cover (PDF)
- Full Article (XML)

Case Report

World J Clin Cases. Aug 16, 2021; 9(23): 6922-6928
Published online Aug 16, 2021. doi: 10.12998/wjcc.v9.i23.6922

Complete withdrawal of glucocorticoids after dupilumab therapy in allergic bronchopulmonary aspergillosis: A case report

Tadashi Nishimura, Tomohito Okano, Masahiro Naito, Chikashi Tsuji, Soichi Iwanaka, Yasumasa Sakakura, Taro Yasuma, Hajime Fujimoto, Corina N D'Alessandro-Gabazza, Yasuhiro Oomoto, Tetsu Kobayashi, Esteban C Gabazza, Hidenori Ibata

Tadashi Nishimura, Masahiro Naito, Chikashi Tsuji, Soichi Iwanaka, Yasumasa Sakakura, Yasuhiro Oomoto, Hidenori Ibata, Department of Pulmonary Medicine, Mie Chuo Medical Center, Tsu 514-1101, Mie, Japan

Tomohito Okano, Hajime Fujimoto, Department of Pulmonary and Critical Care Medicine, Mie University, Tsu 514-8507, Mie, Japan

Taro Yasuma, Corina N D'Alessandro-Gabazza, Esteban C Gabazza, Department of Immunology, Mie University School of Medicine, Mie University, Tsu 514-8507, Mie, Japan

Tetsu Kobayashi, Department of Pulmonary and Critical Care Medicine, Graduate School of Medicine Mie, Mie University, Tsu 514-8507, Mie, Japan

Author contributions: Nishimura T, Okano T, Tsuji C, Iwanaka S, and Sakakura Y were responsible for clinical treatment and clinical follow-up and manuscript preparation; Naito M, Ibata H, and Oomoto Y contributed with resources and acquisition of data; Fujimoto H, D'Alessandro-Gabazza CN, Yasuma T, Kobayashi T, and Gabazza EC contributed to interpreting the data and made an intellectual contribution to the manuscript's preparation. All Authors reviewed and approved the final manuscript.

Informed consent statement: Informed consent was obtained from the subject involved in the study.

Conflict-of-interest statement: None of the authors declared no conflict of interest concerning this case report.

CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).

Corresponding author: Esteban C Gabazza, MD, PhD, Director, Full Professor, Department of Immunology, Mie University School of Medicine, Mie University, Edobashi 2-174, Tsu 514-8507, Japan. gabazza@doc.medic.mie-u.ac.jp

Received: April 25, 2021
Peer-review started: April 25, 2021
First decision: June 6, 2021
Revised: June 8, 2021
Accepted: June 22, 2021
Article in press: June 22, 2021
Published online: August 16, 2021
Processing time: 102 Days and 6.5 Hours

Core Tip

Core Tip: Allergic bronchopulmonary aspergillosis (ABPA) is an allergic reaction to antigen from Aspergillus species that causes exacerbation of bronchial asthma, eosinophilic pneumonia, and bronchiectasis. Conventional therapy includes the administration of oral glucocorticoids and other antiasthmatic therapy. However, there are intractable cases showing repeated clinical exacerbations of bronchial asthma despite therapy with oral glucocorticoids. Previous reports have shown that the addition of monoclonal antibodies against interleukin (IL)-4/IL-13 or dupilumab to the treatment is effective and allows the reduction in the dose of glucocorticoids in ABPA patients. However, there is no report of complete withdrawal of oral glucocorticoids after therapy with dupilumab in these patients. Here, we report the first case of ABPA in which complete withdrawal of oral glucocorticoid was possible after treatment with dupilumab.